BLU-525 / ZAI Lab, Sanofi - LARVOL DELTA

Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022 (PRNewswire) - "Key Upcoming Milestones...Submit an IND to the FDA for BLU-525 for the treatment of EGFR-mutant NSCLC in the first quarter of 2023; Present initial data from the Phase 1/2 CONCERTO study of BLU-451 in patients with EGFR-mutant NSCLC in the first half of 2023; Present initial data from the Phase 1/2 VELA trial of BLU-222 in CDK2-vulnerable cancers in the first half of 2023."

IND • P1/2 data • Breast Cancer • Endometrial Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Estrogen Receptor Positive Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • HER2 Negative Breast Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • CDK2 • KIT